Top-News

Roche Holding Aktie News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
323,40 CHF
+0,60 CHF
+0,19%
345,31 € 16:23:12 Uhr
Depot/Watchlist
Marktkapitalisierung *
34,95 Mrd. €
Streubesitz
16,26%
KGV
25,93
Dividende
9,70 CHF
Dividendenrendite
3,02%
Index-Zuordnung
-

Roche Holding News

28.02.25 - GlobeNewswire
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study 1,2 DLBCL—an aggressive disease with a high risk of ...
26.02.25 - RiskmasterPro
JP Morgan stuft Roche auf Underweight – Negative Aussichten für die Aktie
Neueste Nachrichten von RiskMasterPro (Auszug) Die Roche AG steht unter Druck: Nach einer aktuellen Analyse stuft die US-Bank JPMorgan die Aktie auf ‚Underweight‘ und setzt ...
23.02.25 - wallstreetONLINE Redaktion
Crash-Vorsorge: 1 krisensichere Dividenden-Aktie mit 3,3 % Rendite & 38 Jahre Dividendenwachstum
Starinvestor Warren Buffett erhöht zunehmend die Defensive. Diese Aktie erfüllt viele seiner Kriterien.Gerade wenn Aktien stetig steigen, erscheint ein größerer Rückschlag ...
21.02.25 - RiskmasterPro
Roche AG: UBS empfiehlt Kauf der Aktie
Neueste Nachrichten von RiskMasterPro (Auszug) Roche AG steht im Fokus der Anleger, nachdem die UBS die Aktie mit einer „Buy“-Einstufung und einem Kursziel von 338 Franken ...
20.02.25 - GlobeNewswire
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-​generation sequencing (NGS), which is playing a vital role in decoding complex ...
20.02.25 - RiskmasterPro
Roche unter Druck: Deutsche Bank senkt Bewertung auf „Sell“
Neueste Nachrichten von RiskMasterPro (Auszug) Ein Rückschlag für Roche: Die Deutsche Bank hat die Aktie des Pharmakonzerns auf „Sell“ herabgestuft und das Kursziel auf 265 ...
12.02.25 - GlobeNewswire
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Evrysdi is the only non-​invasive disease-​modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same ...
07.02.25 - GlobeNewswire
New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis
Nearly half of patients on Gazyva/Gazyvaro plus standard therapy achieved a complete renal response (CRR), with a statistically significant and clinically meaningful improvement, ...
04.02.25 - GlobeNewswire
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per ...
31.01.25 - GlobeNewswire
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow. 1 ...
30.01.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
Basel, 30 January 2025
30.01.25 - GlobeNewswire
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2024 mit Verkaufswachstum von 7%; drittes Quartal in Folge mit 9% Wachstum
Basel, 30. Januar 2025
29.01.25 - GlobeNewswire
Change to the Roche Enlarged Corporate Executive Committee
Basel, 29 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that  Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), ...
28.01.25 - GlobeNewswire
Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer
Updated overall survival (OS) results - a key secondary endpoint - reinforce the significant benefit of the Itovebi TM (inavolisib)-based regimen for patients with advanced PIK3CA -...
27.01.25 - GlobeNewswire
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)
Across three key functional outcomes, North Star Ambulatory Assessment (NSAA), Time to Rise (TTR) and 10-meter walk/run (10MWR), results were statistically significant and ...
22.01.25 - GlobeNewswire
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care
More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old, most of which are asymptomatic. 1 FDA CLIA-​waived ...
08.01.25 - GlobeNewswire
Roche purchases shares in tender offer for Poseida Therapeutics, Inc.
Basel, 8 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Blue Giant Acquisition Corp. has accepted for payment all ...
19.12.24 - GlobeNewswire
Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease
PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints Prasinezumab continues to be well tolerated and ...
18.12.24 - GlobeNewswire
Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution
Roche launches its cobas ® Mass Spec solution, bringing mass spectrometry to the routine clinical lab Clinical mass spectrometry testing offers unparalleled sensitivity and ...
13.12.24 - GlobeNewswire
Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
Vabysmo PFS is the first and only prefilled syringe containing a bispecific antibody, offering a convenient alternative to currently available Vabysmo vials Vabysmo has demonstrated ...

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »